[Pre-Aug 2018] IMSCAR

  1. Published

    Adverse drug reactions: analysis by regulatory authorities and by economists

    Hughes, D. & Hughes, D. A., 1 Apr 2007.

    Research output: Contribution to conferencePaper

  2. Published

    Alcohol age of initiation and long-term impact: a cross sectional survey of adults in England

    Morleo, M., Jones, L. & Bellis, M. A., 30 Oct 2014, In: Journal of Substance Use.

    Research output: Contribution to journalArticlepeer-review

  3. Published
  4. Published
  5. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/ReportCommissioned report

  6. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/ReportCommissioned report

  7. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  8. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  9. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  10. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

Previous 1...4 5 6 7 8 9 10 11 ...78 Next